KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Debt to Equity (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Debt to Equity data on record, last reported at $0.81 in Q3 2025.

  • For Q3 2025, Debt to Equity fell 19.29% year-over-year to $0.81; the TTM value through Sep 2025 reached $0.81, down 19.29%, while the annual FY2024 figure was $0.74, 48.33% down from the prior year.
  • Debt to Equity reached $0.81 in Q3 2025 per SRPT's latest filing, down from $0.84 in the prior quarter.
  • Across five years, Debt to Equity topped out at $4.01 in Q4 2022 and bottomed at $0.74 in Q4 2024.
  • Average Debt to Equity over 5 years is $1.66, with a median of $1.44 recorded in 2023.
  • Peak YoY movement for Debt to Equity: soared 239.41% in 2022, then tumbled 64.09% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $1.18 in 2021, then skyrocketed by 239.41% to $4.01 in 2022, then crashed by 64.09% to $1.44 in 2023, then plummeted by 48.33% to $0.74 in 2024, then increased by 9.01% to $0.81 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.81 in Q3 2025, $0.84 in Q2 2025, and $1.0 in Q1 2025.